Kisspeptin-10 Evidence Guide
Evidence for Kisspeptin-10 is too preliminary to support a research protocol with confidence. Human data is largely limited to acute IV challenge studies characterizing LH pulse responses; no Phase 3 reproductive indication has been established. Of the reproductive/hormonal compounds, gonadorelin has more established clinical use as a starting point.
Our Take
Evidence for Kisspeptin-10 is too preliminary to support a research protocol with confidence. Human data is largely limited to acute IV challenge studies characterizing LH pulse responses; no Phase 3 reproductive indication has been established. Of the reproductive/hormonal compounds, gonadorelin has more established clinical use as a starting point.
- Evidence context
- Reproductive neuroendocrinology research, GnRH axis characterization, LH pulse dynamics
- Evidence grade
- Level B
- Confidence
- Low
- Reference context
- Reported research reference: No validated outpatient human protocol - clinical studies use 0.313-3.13nmol/kg IV bolus
Benefits and Evidence
- LH/FSH Stimulation: Level B, includes human evidence - Consistent and potent stimulation of LH and FSH release in human studies. Reliable gonadotropin response in both sexes.
- Testosterone Elevation: Level B, includes human evidence - Dhillo et al. (2005, J Clin Endocrinol Metab) showed IV kisspeptin-10 at 0.3-1 nmol/kg increased plasma testosterone 2-3 fold in healthy men within 90 min; George et al. (2011, J Clin Invest) confirmed sustained LH/testosterone elevation with pulsatile infusion in hypogonadal men.
- Ovulation Triggering: Level B, includes human evidence - Clinical trials demonstrate kisspeptin can trigger oocyte maturation in IVF with reduced risk of ovarian hyperstimulation syndrome compared to hCG.
Side Effects and Warnings
- Generally well-tolerated in clinical trials
- Warmth or flushing
- Mild headache
- Possible tachyphylaxis with repeated dosing
- Investigational peptide, not FDA-approved
- Continuous exposure may lead to receptor desensitization
- Effects on hormone-sensitive conditions not fully studied
- Not for use in hormone-dependent cancers
Research Dosage References
- <strong>Intravenous</strong> - 1-10 mcg/kg - Single dose or infusion - Research dosing. Most human studies use IV administration for controlled pharmacokinetics.
- <strong>Subcutaneous</strong> - 3-10 mcg/kg - Once or twice daily - Explored for repeated dosing protocols. Response may diminish with continuous exposure (tachyphylaxis).
Mechanism of Action
Kisspeptin-10 regulates reproductive hormones: 1. GnRH stimulation: Activates KISS1R on GnRH neurons, triggering robust gonadotropin-releasing hormone secretion. 2. LH/FSH release: Downstream stimulation of luteinizing hormone and follicle-stimulating hormone from the pituitary. 3. Testosterone increase: In males, increased LH drives testicular testosterone production. 4. Ovulation trigger: In females, kisspeptin-induced LH surge can trigger ovulation, potentially replacing hCG in IVF protocols. 5. Puberty regulation: Natural kisspeptin signaling is essential for puberty onset.
Legal Status
Investigational peptide in Phase 2 clinical trials. Not FDA-approved. Available for research purposes. Active area of pharmaceutical development for fertility and reproductive health applications.
Primary Sources
- Kisspeptin as a trigger for oocyte maturation in IVF. N Engl J Med, 2017.
- Kisspeptin-54 triggers egg maturation in women undergoing IVF. J Clin Invest, 2014.
Quick Answers
Where is the strongest evidence for Kisspeptin-10?
Evidence for Kisspeptin-10 is too preliminary to support a research protocol with confidence. Human data is largely limited to acute IV challenge studies characterizing LH pulse responses; no Phase 3 reproductive indication has been established. Of the reproductive/hormonal compounds, gonadorelin has more established clinical use as a starting point. Evidence context: Reproductive neuroendocrinology research, GnRH axis characterization, LH pulse dynamics.
What are the main side effects of Kisspeptin-10?
Kisspeptin-10 side effects and warning signals include Generally well-tolerated in clinical trials, Warmth or flushing, Mild headache, Possible tachyphylaxis with repeated dosing, and Investigational peptide, not FDA-approved.
What evidence level is Kisspeptin-10?
Kisspeptin-10 is rated Level B; the listed research status is Phase 2.
Popular Questions
- Kisspeptin-10 Benefits: Evidence, Verdict, and Limits
- Kisspeptin-10 Side Effects: Safety Signals and Warnings
- Kisspeptin-10 Research Dosage: Published Protocol Reference
- Is Kisspeptin-10 Legit? Evidence Grade and Plain-English Verdict
- Kisspeptin-10 Legal Status: Approval, Research Use, and Regulatory Notes